In the Press

This study aimed to investigate the frequency and characteristics of respiratory co-infections in COVID-19 patients in the intensive care unit (ICU).

Scientists have designed a temporary, battery-free pacemaker that can be broken down by the patient’s body when its work is done, the latest advance in the emerging field of bioelectronics.

Aortic valve stenosis (AS) is a common, lethal cardiovascular disease.

Medical researchers led by Kyushu University have revealed a possible underlying genetic pathway behind the neurological dysfunction of Rett syndrome.

Development of CRISPR-based epigenome editing tools is important for the study and engineering of biological behavior

Harmful bacteria are hiding in livestock; traditional methods aren’t finding them

In hospital, routine disinfection and HVAC system should be combined to control airborne diseases.5,6

The microbiome is the vast collection of bacteria in the human gut.

A novel therapeutic may halt rapid kidney function in some type 1 diabetic kidney disease patients.

Saint Herblain (France), July 7, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the U.S